tetano
Editor, Senior Moderator
J Cardiol Cases
. 2021 Sep 15.
doi: 10.1016/j.jccase.2021.08.012. Online ahead of print.
Takotsubo syndrome after receiving the COVID-19 vaccine
Colleen Fearon[SUP] 1 [/SUP], Purvi Parwani[SUP] 1 [/SUP], Benjamin Gow-Lee[SUP] 1 [/SUP], Dmitry Abramov[SUP] 1 [/SUP]
Affiliations
Abstract
The coronavirus disease (COVID)-19 pandemic has affected millions worldwide with prevention efforts culminating in the development of a vaccine. An mRNA vaccine, developed by Moderna (Cambridge, MA, USA), mounts an immunologic response leading to antibody neutralization. Commonly reported vaccine side effects include myalgia, fever, and chills, with low reported rates of cardiovascular events. This case demonstrates the development of takotsubo syndrome (TTS) after administration of the COVID-19 vaccine. A 73-year-old woman with recently diagnosed myocardial infarction with no obstructive coronary atherosclerosis (MINOCA) presented with typical chest pain starting less than a day after receiving the Moderna vaccine. She had troponin elevations and new ST-segment abnormalities. Transthoracic echocardiogram (TTE) findings were consistent with mid-ventricular TTS. Treatment included diuretics, beta-blockers, and angiotensin receptor blockers. Prior to discharge, repeat imaging showed improvement in systolic function. This case presents a post-menopausal woman with a recent diagnosis of MINOCA who developed TTS shortly after receiving the COVID-19 vaccine. Risk factors including sex, age, MINOCA, anxiety about the vaccine, and possibly the vaccine itself may have all contributed to the TTS presentation. TTS may occur after COVID-19 vaccination, and appreciation of this potential rare association is important for evaluating vaccine safety and optimizing patient outcomes.
Keywords: COVID-19; Case report; Moderna; Stress-induced cardiomyopathy; Takotsubo cardiomyopathy; Takotsubo syndrome; Vaccine.
. 2021 Sep 15.
doi: 10.1016/j.jccase.2021.08.012. Online ahead of print.
Takotsubo syndrome after receiving the COVID-19 vaccine
Colleen Fearon[SUP] 1 [/SUP], Purvi Parwani[SUP] 1 [/SUP], Benjamin Gow-Lee[SUP] 1 [/SUP], Dmitry Abramov[SUP] 1 [/SUP]
Affiliations
- PMID: 34539938
- PMCID: PMC8440167
- DOI: 10.1016/j.jccase.2021.08.012
Abstract
The coronavirus disease (COVID)-19 pandemic has affected millions worldwide with prevention efforts culminating in the development of a vaccine. An mRNA vaccine, developed by Moderna (Cambridge, MA, USA), mounts an immunologic response leading to antibody neutralization. Commonly reported vaccine side effects include myalgia, fever, and chills, with low reported rates of cardiovascular events. This case demonstrates the development of takotsubo syndrome (TTS) after administration of the COVID-19 vaccine. A 73-year-old woman with recently diagnosed myocardial infarction with no obstructive coronary atherosclerosis (MINOCA) presented with typical chest pain starting less than a day after receiving the Moderna vaccine. She had troponin elevations and new ST-segment abnormalities. Transthoracic echocardiogram (TTE) findings were consistent with mid-ventricular TTS. Treatment included diuretics, beta-blockers, and angiotensin receptor blockers. Prior to discharge, repeat imaging showed improvement in systolic function. This case presents a post-menopausal woman with a recent diagnosis of MINOCA who developed TTS shortly after receiving the COVID-19 vaccine. Risk factors including sex, age, MINOCA, anxiety about the vaccine, and possibly the vaccine itself may have all contributed to the TTS presentation. TTS may occur after COVID-19 vaccination, and appreciation of this potential rare association is important for evaluating vaccine safety and optimizing patient outcomes.
Keywords: COVID-19; Case report; Moderna; Stress-induced cardiomyopathy; Takotsubo cardiomyopathy; Takotsubo syndrome; Vaccine.